KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Long-Term Investments (2016 - 2025)

Historic Long-Term Investments for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $291.0 million.

  • AbbVie's Long-Term Investments rose 898.88% to $291.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $291.0 million, marking a year-over-year increase of 898.88%. This contributed to the annual value of $279.0 million for FY2024, which is 822.37% down from last year.
  • AbbVie's Long-Term Investments amounted to $291.0 million in Q3 2025, which was up 898.88% from $310.0 million recorded in Q2 2025.
  • AbbVie's 5-year Long-Term Investments high stood at $310.0 million for Q2 2025, and its period low was $235.0 million during Q3 2022.
  • In the last 5 years, AbbVie's Long-Term Investments had a median value of $275.0 million in 2023 and averaged $275.5 million.
  • As far as peak fluctuations go, AbbVie's Long-Term Investments surged by 29102.56% in 2021, and later plummeted by 1475.41% in 2022.
  • Quarter analysis of 5 years shows AbbVie's Long-Term Investments stood at $277.0 million in 2021, then dropped by 13.0% to $241.0 million in 2022, then rose by 26.14% to $304.0 million in 2023, then decreased by 8.22% to $279.0 million in 2024, then increased by 4.3% to $291.0 million in 2025.
  • Its last three reported values are $291.0 million in Q3 2025, $310.0 million for Q2 2025, and $287.0 million during Q1 2025.